The results showed that rTMS treatment significantly decreased the levels of APP (AD+rTMS: 67.1 ± 10.0% relative to AD, p < 0.05 vs. AD; Figures 3C,D) and β-secretase-generated C99 (AD+rTMS: 84.2 ± 6.7% relative to AD, p < 0.05 vs. AD; Figures 3C,D) and C89 (AD+rTMS: 84.7 ± 5.6% relative to AD, p < 0.05 vs. AD; Figures 3C,D) fragments, as well as BACE1 (AD+rTMS: 81.7 ± 1.8% relative to AD, p < 0.01 vs. AD; Figures 3C,D), compared with AD mice without treatment with rTMS. The gene discussed is APP; the disease is Alzheimer disease.